Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Lucid Diagnostics (LUCD) EBITDA Margin (2021 - 2026)

Lucid Diagnostics filings provide 5 years of EBITDA Margin readings, the most recent being 1563.13% for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 259697.0% to 1563.13% in Q4 2025 year-over-year; TTM through Dec 2025 was 257.68%, a 80199.0% increase, with the full-year FY2025 number at 259.19%, up 80045.0% from a year prior.
  • EBITDA Margin hit 1563.13% in Q4 2025 for Lucid Diagnostics, up from 979.92% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 1563.13% in Q4 2025 to a low of 18917.11% in Q3 2022.
  • Median EBITDA Margin over the past 5 years was 1421.2% (2023), compared with a mean of 3819.43%.
  • Biggest five-year swings in EBITDA Margin: tumbled -1566211bps in 2022 and later skyrocketed 1749590bps in 2023.
  • Lucid Diagnostics' EBITDA Margin stood at 3747.0% in 2021, then tumbled by -257bps to 13370.54% in 2022, then skyrocketed by 92bps to 1101.25% in 2023, then increased by 6bps to 1033.83% in 2024, then soared by 251bps to 1563.13% in 2025.
  • The last three reported values for EBITDA Margin were 1563.13% (Q4 2025), 979.92% (Q3 2025), and 948.67% (Q2 2025) per Business Quant data.